Menu Search
Equities

Vivesto AB

OMAX:BER

Vivesto AB

Actions
  • Price (EUR)0.022
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+34.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 15:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-98.92m
  • Incorporated1988
  • Employees4.00
  • Location
    Vivesto ABGustav III:s Boulevard 46, 5trSOLNA 169 73SwedenSWE
  • Phone+46 18505440
  • Fax+46 18510873
  • Websitehttps://www.vivesto.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.